Cannabinoids for the Treatment of Glaucoma: A Review
Document Type
Article
Publication Title
Medical Cannabis and Cannabinoids
Abstract
Background: Glaucoma is an ocular disease with significant health burden. Despite the availability of many antiglaucoma drugs, a significant proportion of patients may experience worsening of the disease. Hence, there is a need for newer antiglaucoma drugs. Summary: Natural and synthetic derivatives of cannabis plants have been studied in the treatment of glaucoma since the 1970s. This review describes the potential mechanisms of the cannabinoids in the treatment of glaucoma, summarizes the findings of clinical studies describing the efficacy of these compounds, and describes the adverse effects observed with the various cannabinoid formulations evaluated in clinical studies of glaucoma in healthy volunteers and patients. The implications of these findings in terms of the potential clinical status of cannabinoids in the treatment of glaucoma and the challenges involved have also been described. Key Messages: Cannabinoids lower intraocular pressure. However, the effect is short-lived. There is also a lack of well-formulated ocular delivery system. The available evidence is inadequate to recommend the use of cannabinoids for the routine treatment of glaucoma.
First Page
183
Last Page
192
DOI
10.1159/000541461
Publication Date
9-16-2024
Recommended Citation
Joshi, Neeraj; Mariam, Haifa; and Kamath, Ashwin, "Cannabinoids for the Treatment of Glaucoma: A Review" (2024). Open Access archive. 10042.
https://impressions.manipal.edu/open-access-archive/10042
